The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Leukemia L1210

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Leukemia L1210


High impact information on Leukemia L1210


Chemical compound and disease context of Leukemia L1210


Biological context of Leukemia L1210


Anatomical context of Leukemia L1210


Gene context of Leukemia L1210


Analytical, diagnostic and therapeutic context of Leukemia L1210


  1. Differential competition with cytotoxic agents: an approach to selectivity in cancer chemotherapy. Rabinowitz, M., Uehara, Y., Vistica, D.T. Science (1979) [Pubmed]
  2. Phenylthioalkylamines in experimental tumor treatment in mice. DiStefano, V., Evans, I., Myers-Robfogel, M., Estes, J., Godleski, S.A. J. Natl. Cancer Inst. (1983) [Pubmed]
  3. Infused L-histidinol and cisplatin: schedule, specificity, and proliferation dependence. Edelstein, M.B. J. Natl. Cancer Inst. (1989) [Pubmed]
  4. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. Dicker, A.P., Waltham, M.C., Volkenandt, M., Schweitzer, B.I., Otter, G.M., Schmid, F.A., Sirotnak, F.M., Bertino, J.R. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  5. Components of hematoporphyrin derivatives and their tumor-localizing capacity. Kessel, D. Cancer Res. (1982) [Pubmed]
  6. Spermidine requirement for cell proliferation in eukaryotic cells: structural specificity and quantitation. Porter, C.W., Bergeron, R.J. Science (1983) [Pubmed]
  7. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Cadman, E., Heimer, R., Davis, L. Science (1979) [Pubmed]
  8. Augmentation of hematoporphyrin uptake and in vitro-growth inhibition of L1210 leukemia cells by succinylacetone. Ebert, P.S., Hess, R.A., Tschudy, D.P. J. Natl. Cancer Inst. (1985) [Pubmed]
  9. Histidinol-mediated enhancement of the specificity of two anticancer drugs in mice bearing leukemic bone marrow disease. Warrington, R.C., Fang, W.D. J. Natl. Cancer Inst. (1985) [Pubmed]
  10. In vitro assessment of cytotoxic agents in murine cancers: comparison between antiproliferative and antimetabolic assays. Roobol, C., Sips, H.C., Theunissen, J., Atassi, G., Bernheim, J.L. J. Natl. Cancer Inst. (1984) [Pubmed]
  11. Effect of adriamycin on the reproductive integrity of cultured leukemia L1210 and P388 cells. Wilkott, L.J., Dulmadge, E.A., Lloyd, H.H. J. Natl. Cancer Inst. (1978) [Pubmed]
  12. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents. Glae, G.R., Atkins, L.M., Meischen, S.J., Smith, A.B., Walker, E.M. J. Natl. Cancer Inst. (1976) [Pubmed]
  13. Cellular quantitation of in vivo effects of 1-beta-D-arabinofuranosylcytosine on leukemia L1210. Edelstein, M., Valeriote, F., Vietti, T. J. Natl. Cancer Inst. (1977) [Pubmed]
  14. Comparison of in vitro and in vivo effects of thymidine on L1210 leukemia in mice. Zaharko, D.S., Ramonas, L.M. J. Natl. Cancer Inst. (1982) [Pubmed]
  15. Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice. Presant, C.A., Coulter, D., Valeriote, F., Vietti, T.J. J. Natl. Cancer Inst. (1981) [Pubmed]
  16. Cyclic adenosine 3':5'-monophosphate-dependent protein phosphorylation and the control of leukemia L1210 cell growth. Mednieks, M.I., Jungmann, R.A., DeWys, W.D. Cancer Res. (1982) [Pubmed]
  17. DNA damage and repair in mouse leukemia L1210 cells treated with nitrogen mustard, 1,3-bis(2-chloroethyl)-1-nitrosourea, and other nitrosoureas. Ewig, R.A., Kohn, K.W. Cancer Res. (1977) [Pubmed]
  18. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Kirshenbaum, M.R., Chen, S.F., Behrens, C.H., Papp, L.M., Stafford, M.M., Sun, J.H., Behrens, D.L., Fredericks, J.R., Polkus, S.T., Sipple, P. Cancer Res. (1994) [Pubmed]
  19. Flow cytometric analysis by bromodeoxyuridine/DNA assay of cell cycle perturbation of methotrexate-treated mouse L1210 leukemia cells. Tsurusawa, M., Niwa, M., Katano, N., Fujimoto, T. Cancer Res. (1988) [Pubmed]
  20. An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Vilpo, J.A., Vilpo, L.M., Szymkowski, D.E., O'Donovan, A., Wood, R.D. Mol. Cell. Biol. (1995) [Pubmed]
  21. Biological characterization of a prolonged antileukemic effect of 5-azacytidine. Presant, C.A., Valeriote, F., Vietti, T.J. Cancer Res. (1977) [Pubmed]
  22. Correspondence re: J. H. Pincus, A. K. Jameson, and A. E. Brandt. Immunotherapy of L1210 leukemia using neuraminidase-modified plasma membranes combined with chemotherapy. Cancer Res., 41: 3082-3086, 1981. Brandt, A.E. Cancer Res. (1982) [Pubmed]
  23. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Poser, R.G., Sirotnak, F.M., Chello, P.L. Cancer Res. (1981) [Pubmed]
  24. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy. Giampietri, A., Bonmassar, A., Puccetti, P., Circolo, A., Goldin, A., Bonmassar, E. Cancer Res. (1981) [Pubmed]
  25. The L1210 leukemia cell bears a B lymphocyte specific, non-H-2 linked alloantigen. Freund, J.G., Ahmed, A., Budd, R.E., Dorf, M.E., Sell, K.W., Vannier, W.E., Humphreys, R.E. J. Immunol. (1976) [Pubmed]
  26. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Keller, R.P., Altermatt, H.J., Nooter, K., Poschmann, G., Laissue, J.A., Bollinger, P., Hiestand, P.C. Int. J. Cancer (1992) [Pubmed]
  27. Inhibition of murine thymidylate synthase and human dihydrofolate reductase by 5,8-dideaza analogues of folic acid and aminopterin. Hynes, J.B., Patil, S.A., Tomazic, A., Kumar, A., Pathak, A., Tan, X.H., Li, X.Q., Ratnam, M., Delcamp, T.J., Freisheim, J.H. J. Med. Chem. (1988) [Pubmed]
  28. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Rappa, G., Lorico, A., Liu, M.C., Kruh, G.D., Cory, A.H., Cory, J.G., Sartorelli, A.C. Biochem. Pharmacol. (1997) [Pubmed]
  29. Effect of doxorubicin on wild-type and deoxyadenosine-resistant mouse leukemia L1210 cells. He, A.W., Cory, J.G. Int. J. Oncol. (1999) [Pubmed]
  30. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside. Presant, C.A., Vietti, T.J., Valeriote, F., Coulter, D.M. J. Natl. Cancer Inst. (1981) [Pubmed]
  31. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Li, L.H., DeKoning, T.F., Kelly, R.C., Krueger, W.C., McGovren, J.P., Padbury, G.E., Petzold, G.L., Wallace, T.L., Ouding, R.J., Prairie, M.D. Cancer Res. (1992) [Pubmed]
  32. Effect of intravenous infusion of 5-aza-2'-deoxycytidine on survival time of mice with L1210 leukemia. Momparier, R.L., Gonzales, F.A. Cancer Res. (1978) [Pubmed]
  33. Properties of uridine-cytidine kinase derived from L1210 leukemia cells. Ahmed, N.K., Baker, D.R. Cancer Res. (1980) [Pubmed]
WikiGenes - Universities